Palabras clave
lncRNA
Pronóstico
Resistencia
GAS5
Cómo citar
Copyright © | Todos los derechos reservados.
La revista posee los derechos de autor exclusivos para la publicación de este artículo en los términos de la ley brasileña 9610/98.
Reproducción parcial
El uso de partes de los textos, figuras y cuestionario del artículo es libre, siendo obligatoria la citación de los autores y revista.
Reproducción total
Está expresamente prohibido y debe ser autorizado por la revista.
Resumen
Objetivo: Identificar lncRNAs asociados con la resistencia a la quimioterapia en el cáncer cervical (CC). Métodos: Este estudio es una revisión sistemática de la literatura realizada de acuerdo con las directrices del Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). El protocolo fue previamente registrado en el International Prospective Register of Systematic Reviews (PROSPERO) bajo el código CRD42023432017. Las búsquedas se realizaron en bases de datos como PubMed, ScienceDirect y Web of Science, lo que resultó en la selección de 21 artículos publicados entre 2017 y 2023. Resultados: Los hallazgos destacaron que 19 lncRNAs están implicados en la resistencia a cuatro agentes quimioterapéuticos, incluido GAS5, que fue el objetivo del mayor número de estudios. Estos lncRNAs están involucrados en la resistencia al paclitaxel (PTX), al 5-fluorouracilo (5-FU) y a la doxorrubicina (DTX). Consideraciones finales: Estos resultados resaltan la importancia de los lncRNAs como posibles marcadores de respuesta al tratamiento y sugieren que la regulación mediada por miRNAs puede influir diretamente en vías biológicas que se encuentran frecuentemente desreguladas en el cáncer.
Referencias
BHATTACHARJEE R, et al. Cellular landscaping of cisplatin resistance in cervical cancer. Biomed Pharmacother, 2022; 153: 113345.
BRAY F, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018; 68(6): 394–424.
BRANDÃO HN, et al. Química e farmacologia de quimioterápicos antineoplásicos derivados de plantas. Quim Nova, 2010; 33(6): 1359–69.
CAO S, et al. Decreased expression of lncRNA GAS5 predicts a poor prognosis in cervical cancer. Int J Clin Exp Pathol, 2014; 7(10): 6776–83.
CHEN W, et al. Nomogram for prognosis of elderly patients with cervical cancer who receive combined radiotherapy. Sci Rep, 2023; 13(1): 13299.
DU Y, et al. LncRNA MEG3 promotes cisplatin sensitivity of cervical cancer cells by regulating the miR-21/PTEN axis. BMC Cancer, 2022; 22(1): 1145.
FANG X, et al. Low GAS5 expression may predict poor survival and cisplatin resistance in cervical cancer. Cell Death Dis, 2020; 11(7): 531.
FARZANEH M, et al. Emerging roles of the long non-coding RNA NEAT1 in gynecologic cancers. J Cell Commun Signal, 2023; 17(3): 531–47.
FENG L-L, et al. Expression of the lncRNA ZFAS1 in cervical cancer and its correlation with prognosis and chemosensitivity. Gene, 2019; 696: 105–12.
GHOSH S. Cisplatin: The first metal based anticancer drug. Bioorg Chem, 2019; 88: 102925.
GIDDINGS EL, et al. Mitochondrial ATP fuels ABC transporter-mediated drug efflux in cancer chemoresistance. Nat Commun, 2021; 12(1): 2804.
HE J, et al. Long non-coding RNA in cervical cancer: From biology to therapeutic opportunity. Biomed Pharmacother, 2020; 127: 110209.
HE S, et al. The role of the SOX9/lncRNA ANXA2P2/miR-361-3p/SOX9 regulatory loop in cervical cancer cell growth and resistance to cisplatin. Front Oncol, 2021; 11: 784525.
INSTITUTO NACIONAL DE CÂNCER (INCA). Estimativa 2023: incidência de câncer no Brasil. Rio de Janeiro: INCA, 2023.
JOHNSON CA, et al. Cervical cancer: An overview of pathophysiology and management. Semin Oncol Nurs, 2019; 35(2): 166–74.
LIU M, et al. Expression of micro-RNA-492 (MiR-492) in human cervical cancer cell lines is upregulated by transfection with wild-type P53, irradiation, and 5-fluorouracil treatment in vitro. Med Sci Monit, 2018; 24: 7750–8
.
LIU MY, LI N. The diagnostic value of lncRNA HOTAIR for cervical carcinoma in vaginal discharge and serum. Medicine (Baltimore), 2023; 102(26): e34042.
LIU S, et al. SP1-induced lncRNA DUBR promotes stemness and oxaliplatin resistance of hepatocellular carcinoma via E2F1-CIP2A feedback. Cancer Lett, 2022; 528: 16–30.
LUO X, et al. Exosomal lncRNA HNF1A-AS1 affects cisplatin resistance in cervical cancer cells through regulating microRNA-34b/TUFT1 axis. Cancer Cell Int, 2019; 19: 323.
MAO B-D, et al. LINC00511 knockdown prevents cervical cancer cell proliferation and reduces resistance to paclitaxel. J Biosci, 2019; 44(2).
MARKMAN M. Advances in cervical cancer pharmacotherapies. Expert Rev Clin Pharmacol, 2014; 7(2): 219–23.
MECENAS P, et al. Effects of temperature and humidity on the spread of COVID-19: A systematic review. PLoS One, 2020; 15(9): e0238339.
METHLEY AM, et al. PICO, PICOS and SPIDER: a comparison study of specificity and sensitivity in three search tools for qualitative systematic reviews. BMC Health Serv Res, 2014; 14(1): 579.
MODABBER N, et al. Evaluation of long non-coding RNA (lncRNA) in the pathogenesis of chemotherapy resistance in cervical cancer: diagnostic and prognostic approach. Mol Biotechnol, 2024; 66(10): 2751–2763.
ORGANIZAÇÃO PAN-AMERICANA DA SAÚDE (OPAS). Câncer do colo do útero. Washington, DC: OPAS.
PAGE MJ, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ, 2021; 372: n71.
PAVLOVA NN, THOMPSON CB. The emerging hallmarks of cancer metabolism. Cell Metab, 2016; 23(1): 27–47.
QU S, et al. MiR-361-3p regulates liver tumor-initiating cells expansion and chemo-resistance. J Cancer, 2021; 12(5): 1483–92.
SAW PE, et al. Non-coding RNAs: the new central dogma of cancer biology. Sci China Life Sci, 2021; 64(1): 22–50.
SETHY C, KUNDU CN. 5-Fluorouracil (5-FU) resistance and the new strategy to enhance the sensitivity against cancer: Implication of DNA repair inhibition. Biomed Pharmacother, 2021; 137: 111285.
SHAO X, et al. Inhibition of lncRNA-NEAT1 sensitizes 5-Fu resistant cervical cancer cells through de-repressing the microRNA-34a/LDHA axis. Biosci Rep, 2021; 41(7).
SHEN C-J, et al. LncRNA PVT1 epigenetically silences miR-195 and modulates EMT and chemoresistance in cervical cancer cells. J Drug Target, 2017; 25(7): 637–44.
SWEEF O, et al. Decoding lncRNA in COPD: unveiling prognostic and diagnostic power and their driving role in lung cancer progression. Int J Mol Sci, 2024; 25(16): 9001.
WAN S, ZHAO H. Analysis of diagnostic and prognostic value of lncRNA MEG3 in cervical cancer. Oncol Lett, 2020; 20(5): 183.
WEN Q, et al. Long noncoding RNA GAS5, which acts as a tumor suppressor via microRNA 21, regulates cisplatin resistance expression in cervical cancer. Int J Gynecol Cancer, 2017; 27(6): 1096–108.
YAO T, et al. Growth arrest-specific 5 attenuates cisplatin-induced apoptosis in cervical cancer by regulating STAT3 signaling via miR-21. J Cell Physiol, 2019; 234(6): 9605–15.
YUAN LY, et al. Involvement of NEAT1/miR-133a axis in promoting cervical cancer progression via targeting SOX4. J Cell Physiol, 2019; 234(10): 18985–18993.
ZHANG L, et al. LncRNA SNHG5 promotes cervical cancer progression by regulating the miR-132/SOX4 pathway. Autoimmunity, 2021; 54(2): 88–96.
ZHANG W, et al. LncRNA HOTAIR promotes chemoresistance by facilitating epithelial to mesenchymal transition through miR-29b/PTEN/PI3K signaling in cervical cancer. Cells Tissues Organs, 2022; 211(1): 16–29.
ZHANG Y, WEN Y. The role of lncRNA NEAT1 in gastric cancer: tumor development and potential therapeutic target. Curr Pharm Des, 2023; 29(28): 2213–22.
ZHOU C, et al. Tislelizumab versus docetaxel in patients with previously treated advanced NSCLC (RATIONALE-303): A phase 3, open-label, randomized controlled trial. J Thorac Oncol, 2023; 18(1): 93–105.